JPH0240681B2 - - Google Patents
Info
- Publication number
- JPH0240681B2 JPH0240681B2 JP62069246A JP6924687A JPH0240681B2 JP H0240681 B2 JPH0240681 B2 JP H0240681B2 JP 62069246 A JP62069246 A JP 62069246A JP 6924687 A JP6924687 A JP 6924687A JP H0240681 B2 JPH0240681 B2 JP H0240681B2
- Authority
- JP
- Japan
- Prior art keywords
- mps
- solution
- complex compound
- acetone
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920000045 Dermatan sulfate Polymers 0.000 claims abstract description 94
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 65
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 17
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 108091005804 Peptidases Proteins 0.000 claims abstract description 6
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 6
- 238000010438 heat treatment Methods 0.000 claims abstract description 5
- 102000035195 Peptidases Human genes 0.000 claims abstract description 4
- 210000001557 animal structure Anatomy 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000006166 lysate Substances 0.000 claims abstract 4
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 90
- 229940051593 dermatan sulfate Drugs 0.000 claims description 90
- 239000000243 solution Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000012266 salt solution Substances 0.000 claims description 6
- UUHBNESUDPIHCI-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.CCCCCCCCCCCCCCCC[N+](C)(C)CC UUHBNESUDPIHCI-UHFFFAOYSA-M 0.000 claims description 5
- 239000011882 ultra-fine particle Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 3
- 108010056079 Subtilisins Proteins 0.000 claims description 3
- 102000005158 Subtilisins Human genes 0.000 claims description 3
- 239000004019 antithrombin Substances 0.000 claims description 3
- 229940115457 cetyldimethylethylammonium bromide Drugs 0.000 claims description 3
- VUFOSBDICLTFMS-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CC VUFOSBDICLTFMS-UHFFFAOYSA-M 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 108090000317 Chymotrypsin Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229960002376 chymotrypsin Drugs 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 15
- 239000002244 precipitate Substances 0.000 abstract description 14
- 239000000843 powder Substances 0.000 abstract description 12
- 150000003863 ammonium salts Chemical class 0.000 abstract description 9
- 210000000056 organ Anatomy 0.000 abstract description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract description 5
- 239000001110 calcium chloride Substances 0.000 abstract description 5
- 235000011148 calcium chloride Nutrition 0.000 abstract description 5
- 229910001628 calcium chloride Inorganic materials 0.000 abstract description 5
- 238000001914 filtration Methods 0.000 abstract description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 abstract description 2
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 abstract 4
- 230000000536 complexating effect Effects 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 230000003019 stabilising effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 241000700159 Rattus Species 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 11
- 239000011575 calcium Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000005063 solubilization Methods 0.000 description 6
- 230000007928 solubilization Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 5
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000011344 liquid material Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003363 arteriovenous anastomosis Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- -1 DS sodium salt Chemical class 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- ITHZDDVSAWDQPZ-UHFFFAOYSA-L barium acetate Chemical compound [Ba+2].CC([O-])=O.CC([O-])=O ITHZDDVSAWDQPZ-UHFFFAOYSA-L 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000008275 galactosamines Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- GGHDAUPFEBTORZ-UHFFFAOYSA-N propane-1,1-diamine Chemical compound CCC(N)N GGHDAUPFEBTORZ-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT19864A/86 | 1986-03-25 | ||
| IT19864/86A IT1189085B (it) | 1986-03-25 | 1986-03-25 | Processo per la preparazione di dermatan solfato ad alta purezza e composizioni farmaceutiche che lo contengono |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62236803A JPS62236803A (ja) | 1987-10-16 |
| JPH0240681B2 true JPH0240681B2 (h) | 1990-09-12 |
Family
ID=11161892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62069246A Granted JPS62236803A (ja) | 1986-03-25 | 1987-03-25 | 高純度デルマタン硫酸の製法およびこれを含有する薬用組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US4870166A (h) |
| EP (1) | EP0238994B1 (h) |
| JP (1) | JPS62236803A (h) |
| KR (1) | KR910006811B1 (h) |
| AT (1) | ATE65250T1 (h) |
| AU (1) | AU599638B2 (h) |
| CA (1) | CA1334516C (h) |
| DE (1) | DE3771362D1 (h) |
| DK (1) | DK122187A (h) |
| ES (1) | ES2029804T3 (h) |
| FI (1) | FI871209A7 (h) |
| GR (1) | GR3002341T3 (h) |
| IE (1) | IE59878B1 (h) |
| IN (1) | IN163520B (h) |
| IT (1) | IT1189085B (h) |
| MX (1) | MX5656A (h) |
| NO (1) | NO167676C (h) |
| PT (1) | PT84491B (h) |
| YU (1) | YU44187A (h) |
| ZA (1) | ZA872081B (h) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5707604A (en) * | 1986-11-18 | 1998-01-13 | Access Pharmaceuticals, Inc. | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles |
| ATE129254T1 (de) * | 1987-03-19 | 1995-11-15 | Arthropharm Pty Ltd | Antientzündungsmittel und zusammensetzungen. |
| US5668116A (en) * | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
| US5141928B1 (en) * | 1989-12-20 | 1995-11-14 | Brujo Inc | Ophthalmic medication |
| AU7742591A (en) * | 1990-04-06 | 1991-10-30 | Washington University | Anticoagulant oligosaccharides |
| IT1251183B (it) * | 1991-08-28 | 1995-05-04 | Opocrin Spa | Dermatan solfato ad alto titolo, dotato di elevata attivita' trombolitica, e forme farmaceutiche che lo contengono. |
| CN1115182A (zh) * | 1993-09-30 | 1996-01-17 | 生化学工业株式会社 | 抗血栓剂 |
| US5696099A (en) * | 1994-04-18 | 1997-12-09 | Lifegroup S.P.A. | Topical preparations for the treatment of acne and acneiform dermatitis |
| CA2121952A1 (en) * | 1994-04-22 | 1995-10-23 | Francesco Della Valle | Topical preparations for the treatment of acne and acneiform dermatitis |
| US6106866A (en) * | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
| US20050164983A1 (en) * | 2003-12-19 | 2005-07-28 | Aventis Pharma S.A. | Carboxyl-reduced derivatives of dermatan sulfate, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them |
| ES2281265B1 (es) | 2005-11-24 | 2008-08-16 | Bioiberica, S.A. | Composiciones para el tratamiento de la artrosis. |
| ES2327480B1 (es) | 2007-06-15 | 2010-08-10 | Bioiberica, S.A. | "disacaridos para el tratamiento de tendones, ligamentos y huesos". |
| ES2440390B1 (es) | 2012-07-25 | 2014-11-13 | Bioibérica, S.A. | Composiciones para el tratamiento del sobrepeso y de la obesidad |
| CN104448044B (zh) * | 2014-12-24 | 2017-01-11 | 南京健友生化制药股份有限公司 | 一种肝素钠的去色与降低硫酸皮肤素含量的方法 |
| CN105461831A (zh) * | 2016-01-08 | 2016-04-06 | 东营天东制药有限公司 | 一种快速分离快速移动肝素与硫酸皮肤素的方法 |
| ES2638195B1 (es) | 2016-04-18 | 2018-08-02 | Bioiberica, S.A. | Composiciones para la piel |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5318520B2 (h) * | 1972-07-05 | 1978-06-15 | ||
| IT1189298B (it) * | 1982-06-18 | 1988-02-04 | Manetti & Roberts Italo Brit | Procedimento per produrre i glicosa minoglicani dermatansolfato ed eparan-solfato sostanzialmente puri e loro impiego farmaceutico |
| IT1208509B (it) * | 1985-03-13 | 1989-07-10 | Mediolanum Farmaceutici Srl | Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico. |
-
1986
- 1986-03-25 IT IT19864/86A patent/IT1189085B/it active
-
1987
- 1987-03-09 NO NO870962A patent/NO167676C/no unknown
- 1987-03-10 DK DK122187A patent/DK122187A/da not_active Application Discontinuation
- 1987-03-16 PT PT84491A patent/PT84491B/pt unknown
- 1987-03-16 YU YU00441/87A patent/YU44187A/xx unknown
- 1987-03-18 AT AT87103943T patent/ATE65250T1/de not_active IP Right Cessation
- 1987-03-18 EP EP87103943A patent/EP0238994B1/en not_active Expired - Lifetime
- 1987-03-18 ES ES198787103943T patent/ES2029804T3/es not_active Expired - Lifetime
- 1987-03-18 DE DE8787103943T patent/DE3771362D1/de not_active Expired - Lifetime
- 1987-03-19 FI FI871209A patent/FI871209A7/fi not_active IP Right Cessation
- 1987-03-19 US US07/027,733 patent/US4870166A/en not_active Expired - Lifetime
- 1987-03-19 IE IE72187A patent/IE59878B1/en not_active IP Right Cessation
- 1987-03-20 MX MX565687A patent/MX5656A/es unknown
- 1987-03-20 ZA ZA872081A patent/ZA872081B/xx unknown
- 1987-03-23 AU AU70540/87A patent/AU599638B2/en not_active Ceased
- 1987-03-23 KR KR1019870002636A patent/KR910006811B1/ko not_active Expired
- 1987-03-24 CA CA000532821A patent/CA1334516C/en not_active Expired - Fee Related
- 1987-03-25 JP JP62069246A patent/JPS62236803A/ja active Granted
- 1987-03-25 IN IN235/CAL/87A patent/IN163520B/en unknown
-
1990
- 1990-10-23 US US07/600,267 patent/US5116963A/en not_active Expired - Fee Related
-
1991
- 1991-07-19 GR GR91401056T patent/GR3002341T3/el unknown
Non-Patent Citations (1)
| Title |
|---|
| CHEM.ABSOR.=1981 * |
Also Published As
| Publication number | Publication date |
|---|---|
| YU44187A (en) | 1988-04-30 |
| US4870166A (en) | 1989-09-26 |
| EP0238994A3 (en) | 1988-09-21 |
| NO167676B (no) | 1991-08-19 |
| KR910006811B1 (ko) | 1991-09-02 |
| IN163520B (h) | 1988-10-01 |
| PT84491B (pt) | 1989-11-10 |
| CA1334516C (en) | 1995-02-21 |
| ES2029804T3 (es) | 1992-10-01 |
| PT84491A (en) | 1987-04-01 |
| ZA872081B (en) | 1987-09-14 |
| DE3771362D1 (de) | 1991-08-22 |
| IT1189085B (it) | 1988-01-28 |
| FI871209A7 (fi) | 1987-09-26 |
| DK122187D0 (da) | 1987-03-10 |
| IE59878B1 (en) | 1994-04-20 |
| NO167676C (no) | 1991-11-27 |
| DK122187A (da) | 1987-09-26 |
| US5116963A (en) | 1992-05-26 |
| AU599638B2 (en) | 1990-07-26 |
| NO870962L (no) | 1987-09-28 |
| FI871209A0 (fi) | 1987-03-19 |
| EP0238994A2 (en) | 1987-09-30 |
| EP0238994B1 (en) | 1991-07-17 |
| JPS62236803A (ja) | 1987-10-16 |
| IT8619864A0 (it) | 1986-03-25 |
| IE870721L (en) | 1987-09-25 |
| MX5656A (es) | 1993-12-01 |
| GR3002341T3 (en) | 1992-12-30 |
| AU7054087A (en) | 1987-10-01 |
| ATE65250T1 (de) | 1991-08-15 |
| KR870008916A (ko) | 1987-10-22 |
| IT8619864A1 (it) | 1987-09-25 |
| NO870962D0 (no) | 1987-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0240681B2 (h) | ||
| FR2482611A1 (fr) | Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments | |
| JPH0323528B2 (h) | ||
| CN100525777C (zh) | 一种解聚海参糖胺聚糖组合物及其制备方法和用途 | |
| US3329572A (en) | Process for treating animal tissues and product | |
| HU190687B (en) | Process for preparing new antithrombotic of polysaccharide base further pharmaceutical compositions containing such substance as active material | |
| JPH03243601A (ja) | 血液凝固の制御能をもつムコ多糖組成物およびその製造方法 | |
| SU581872A3 (ru) | Способ получени ферментного препарата, обладающего гемостатическим и антикоагулирующим действием | |
| JP3279316B2 (ja) | 血栓溶解活性を有するデルマタンスルフェート及びこれを含有する製薬形態 | |
| JP2628507B2 (ja) | Ｅｄｔａ不含のヘパリン、ヘパリン分画ならびに断片、それらの製造法及びそれらを含有する医薬品組成物 | |
| US4115551A (en) | Compounds of the plasminogen type and method for obtaining such compounds from placental pulps | |
| EP0011322B1 (en) | Anticoagulant agent, process for the preparation thereof and pharmaceutical preparations containing same | |
| JPH10182703A (ja) | 低分子量のフカン類とその医薬組成物 | |
| KR102298179B1 (ko) | 비분획 헤파린의 제조방법 | |
| KR0184260B1 (ko) | 항트롬보 활성을 지닌 황산화 글리코스아미노글리큐로난 | |
| KR101780643B1 (ko) | 효소분해를 이용한 헤파린의 정제 방법 | |
| FR2522266A1 (fr) | Procede de preparation d'un agent fibrinolytiquement actif et agent obtenu | |
| JPS63128001A (ja) | Ｆｇａｇ及びその塩、その製造方法並びにそれを含有する播種性血管内凝固症候群治療剤 | |
| RU2302250C1 (ru) | Средство, обладающее антикоагулянтным действием, и способ его получения | |
| JPH0670085B2 (ja) | コンドロイチン硫酸誘導体 | |
| CN101100688A (zh) | 鮟鱇鱼皮中硫酸皮肤素的提取纯化方法 | |
| US2921000A (en) | Thromboplastin | |
| CN116987181B (zh) | 高生物学活性的天然水蛭素和高收率制备它们的方法 | |
| JPS6341921B2 (h) | ||
| RU2096038C1 (ru) | Способ получения агрегатов протеогликанов из соединительной ткани животного (варианты) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |